
Cardiomaticssp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Cardiomatics provides CE/MDR-certified medical software for analyzing Holter ECG recordings using AI algorithms. The cloud-based system supports more than 60 Holter ECG devices and lets users retrieve reports in a web browser. It serves outpatient clinics, primary care providers, and integration partners.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News

From Signal to System: Closing the Diagnostic Gap in Rhythmology

Meet Cardiomatics at the ESC Congress 2026 in Munich

How Poliklinika SERCE Increased Holter ECG Tests by 50% Thanks to Cardiomatics

Arseus Medical and Cardiomatics Implement AI-Based Holter ECG Analysis at Clinique Saint-Luc Bouge

Transform Holter ECG Report Verification into an Additional Service for Your Cardiology Clinic

Introduce Holter ECG Tests to Your Facility with Cardiologist Support in Report Verification
Industry
Bank accounts
Registered as a VAT taxpayer on 2015-05-28. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
16 public aid cases recorded, with a total value of $2,019,636.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 18, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 24, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 31, 2021 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2021-04-01 | Opracowanie innowacyjnego narzędzia do automatycznej oceny zaburzeń rytmu serca i przewodzenia u pacjentów pediatrycznych | $1.0M$1,033,721 | Program Operacyjny Inteligentny Rozwój | |
| 2019-06-01 | Internacjonalizacja marki Cardiomatics na rynkach zagranicznych poprzez udział w międzynarodowych targach branżowych dla IT/ICT | $76,658$76,658 | Program Operacyjny Inteligentny Rozwój | |
| 2018-07-01 | System automatycznej analizy sygnału EKG na potrzeby oceny skuteczności resynchronizacji w terapii CRT | $642.6K$642,607 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Kaya Citrine S.r.o. | 197 | $2,660.72 | 11.3873% |
Mariusz Mateusz Mąsior (40) | 189 | $2,552.67 | 10.9249% |
| 194 | $2,620.21 | 11.2139% | |
Samborscy Fundacja Rodzinna w Organizacji | 803 | $10,845.49 | 46.4162% |
Others | 347 | $4,686.66 | 20.0577% |
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MedicalgorithmicsS.A. | $7,819,186.34 | medicalgorithmics.com | ||
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com | ||
| MLS Softwaresp. z o.o. | $799,143.43 | mls-software.pl | ||
| DigitmedS.A. | $382,907.91 | digitmed.pl | ||
| Cardiocaresp. z o.o. + limited partnership | $381,235.13 | cardiocare.com.pl | ||
| Dicellasp. z o.o. | $322,185.03 | dicella.com | ||
| JAS Analyticssp. z o.o. | $245,699.54 | jasanalytics.eu | ||
| SatroecgS.A. | $219,113.17 | satroecg.pl |
Change history
| Date | Event | |
|---|---|---|
| 2026-10-13 | Share capital change (84,950.00 PLN → 86,500.00 PLN) | |
| 2026-05-15 | Share capital change (81,550.00 PLN → 84,950.00 PLN) | |
| 2021-08-20 | Share capital change (12,450.00 PLN → 81,550.00 PLN) | |
| 2021-03-26 | Share capital change (12,400.00 PLN → 12,450.00 PLN) | |
| 2020-05-14 | Share capital change (12,300.00 PLN → 12,400.00 PLN) |
FAQ
Last updated: 2026-10-13
